OTCMKTS:RHHBY - Roche Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$28.1350 -0.30 (-1.06 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$28.1350
Today's Range$28.10 - $28.37
52-Week Range$27.48 - $34.5150
Volume1.39 million shs
Average Volume2.06 million shs
Market Capitalization$190.35 billion
P/E Ratio14.43
Dividend Yield3.19%
Beta0.55

About Roche (OTCMKTS:RHHBY)

Roche logoRoche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases. The company provides diagnostic solutions, such as blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring; diabetes therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogeneous immuno assays; immunology; infectious diseases; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control service; real-time PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. Roche Holding AG has a strategic alliance with Wisconsin Diagnostic Laboratories. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RHHBY
CUSIPN/A
Phone41-61-688-1111

Debt

Debt-to-Equity Ratio0.55
Current Ratio1.42
Quick Ratio1.09

Price-To-Earnings

Trailing P/E Ratio14.43
Forward P/E Ratio13.86
P/E Growth1.84

Sales & Book Value

Annual Sales$54.15 billion
Price / Sales3.54
Cash Flow$2.5647 per share
Price / Cash10.97
Book Value$4.33 per share
Price / Book6.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees94,052
Outstanding Shares6,815,420,000

Roche (OTCMKTS:RHHBY) Frequently Asked Questions

What is Roche's stock symbol?

Roche trades on the OTCMKTS under the ticker symbol "RHHBY."

What price target have analysts set for RHHBY?

11 Wall Street analysts have issued 1-year target prices for Roche's stock. Their predictions range from $38.00 to $38.00. On average, they anticipate Roche's stock price to reach $38.00 in the next twelve months. View Analyst Ratings for Roche.

Who are some of Roche's key competitors?

Who are Roche's key executives?

Roche's management team includes the folowing people:
  • Ms. Cristina A. Wilbur, Head of Group HR (Age 51)
  • Dr. Severin Schwan, CEO &Exec. Director (Age 51)
  • Dr. Alan Hippe, Chief Financial & IT Officer (Age 51)
  • Dr. Gottlieb A. Keller, Gen. Counsel & Corp. Sec. (Age 64)
  • Dr. Urs Jaisli, Chief Compliance Officer (Age 62)

Has Roche been receiving favorable news coverage?

News coverage about RHHBY stock has been trending somewhat negative this week, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Roche earned a media sentiment score of -0.01 on Accern's scale. They also assigned press coverage about the company an impact score of 46.32 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Roche's major shareholders?

Roche's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.25%), Schafer Cullen Capital Management Inc. (0.04%), Bristol John W & Co. Inc. NY (0.03%), Douglass Winthrop Advisors LLC (0.01%), Grimes & Company Inc. (0.00%) and Kornitzer Capital Management Inc. KS (0.00%). View Institutional Ownership Trends for Roche.

Which major investors are selling Roche stock?

RHHBY stock was sold by a variety of institutional investors in the last quarter, including Schafer Cullen Capital Management Inc., NorthCoast Asset Management LLC, Tower Bridge Advisors, Bristol John W & Co. Inc. NY, KCM Investment Advisors LLC, CT Mason, Lee Danner & Bass Inc. and Opus Capital Group LLC. View Insider Buying and Selling for Roche.

Which major investors are buying Roche stock?

RHHBY stock was acquired by a variety of institutional investors in the last quarter, including Douglass Winthrop Advisors LLC, Fisher Asset Management LLC, Grimes & Company Inc., PVG Asset Management Corp, Summit Global Investments, Scout Investments Inc., Advisor Partners LLC and Hikari Power Ltd. View Insider Buying and Selling for Roche.

How do I buy shares of Roche?

Shares of RHHBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Roche's stock price today?

One share of RHHBY stock can currently be purchased for approximately $28.1350.

How big of a company is Roche?

Roche has a market capitalization of $190.35 billion and generates $54.15 billion in revenue each year. The company earns $8.77 billion in net income (profit) each year or $1.95 on an earnings per share basis. Roche employs 94,052 workers across the globe.

How can I contact Roche?

Roche's mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company can be reached via phone at 41-61-688-1111 or via email at [email protected]


MarketBeat Community Rating for Roche (RHHBY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Roche and other stocks. Vote "Outperform" if you believe RHHBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RHHBY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Roche (OTCMKTS:RHHBY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Roche in the last 12 months. Their average twelve-month price target is $38.00, suggesting that the stock has a possible upside of 35.06%. The high price target for RHHBY is $38.00 and the low price target for RHHBY is $38.00. There are currently 3 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.172.25
Ratings Breakdown: 3 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.00$38.00$38.00$38.00
Price Target Upside: 35.06% upside32.94% upside19.59% upside27.90% upside

Roche (OTCMKTS:RHHBY) Consensus Price Target History

Price Target History for Roche (OTCMKTS:RHHBY)

Roche (OTCMKTS:RHHBY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/10/2018Sanford C. BernsteinDowngradeOutperform ➝ Market PerformView Rating Details
3/27/2018Morgan StanleyDowngradeEqual Weight ➝ UnderweightView Rating Details
1/15/2018Societe GeneraleDowngradeHold ➝ SellView Rating Details
12/29/2017JPMorgan ChaseReiterated RatingOverweight ➝ OverweightView Rating Details
12/7/2017Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
10/24/2017Berenberg BankDowngradeBuy ➝ HoldView Rating Details
10/18/2017CitigroupDowngradeBuy ➝ NeutralView Rating Details
9/26/2017BNP ParibasDowngradeNeutral ➝ UnderperformView Rating Details
9/19/2017CowenReiterated RatingBuy$38.00View Rating Details
7/7/2017Deutsche BankDowngradeBuy ➝ HoldView Rating Details
7/6/2017UBSDowngradeBuy ➝ NeutralView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold ➝ HoldView Rating Details
3/7/2017BarclaysInitiated CoverageOverweightView Rating Details
2/19/2017Jefferies GroupReiterated RatingBuyView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Dividends

Roche (OTCMKTS:RHHBY) Dividend Information

Roche pays an annual dividend of $0.89 per share, with a dividend yield of 3.16%. Roche pays out 45.64% of its earnings out as a dividend.
Annual Dividend:$0.89
Dividend Yield:3.16%
Payout Ratio(s):45.64% (Trailing 12 Months of Earnings)
43.84% (Based on This Year's Estimates)
40.64% (Based on Next Year's Estimates)
34.70% (Based on Cash Flow)
Dividend Payments by Quarter for Roche (OTCMKTS:RHHBY)

Roche (OTCMKTS:RHHBY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Roche (OTCMKTS RHHBY) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.57%
Insider Trading History for Roche (OTCMKTS:RHHBY)
Insider Trading History for Roche (OTCMKTS:RHHBY)

Roche (OTCMKTS RHHBY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Roche (OTCMKTS RHHBY) News Headlines

Source:
DateHeadline
Gene Sieve Receives Tom Roche Lifetime Achievement AwardGene Sieve Receives Tom Roche Lifetime Achievement Award
www.prnewswire.com - May 22 at 5:00 PM
Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
finance.yahoo.com - May 22 at 5:00 PM
Roche’s Ocrevus Witnessed Solid Growth in Q1 2018Roche’s Ocrevus Witnessed Solid Growth in Q1 2018
finance.yahoo.com - May 22 at 5:00 PM
Should You Buy Roche Holding AG (VTX:ROG) At This PE Ratio?Should You Buy Roche Holding AG (VTX:ROG) At This PE Ratio?
finance.yahoo.com - May 22 at 8:30 AM
Roche’s Perjeta Witnessed Solid Growth in Q1 2018Roche’s Perjeta Witnessed Solid Growth in Q1 2018
finance.yahoo.com - May 22 at 8:30 AM
Study Finds More Isnt Better for Roche Breast Cancer DrugStudy Finds More Isn't Better for Roche Breast Cancer Drug
www.bloomberg.com - May 17 at 6:01 PM
Roche immunotherapy combination increases lung cancer survival-studyRoche immunotherapy combination increases lung cancer survival-study
finance.yahoo.com - May 17 at 8:38 AM
Reducing Use of Roche Drug for Breast Cancer Didnt Hurt Efficacy, Study SaysReducing Use of Roche Drug for Breast Cancer Didn't Hurt Efficacy, Study Says
www.wsj.com - May 16 at 5:23 PM
Roche breast cancer drug treatment time can be halved - studyRoche breast cancer drug treatment time can be halved - study
finance.yahoo.com - May 16 at 5:23 PM
Study Finds More Isnt Better for Widely Used Breast Cancer DrugStudy Finds More Isn't Better for Widely Used Breast Cancer Drug
finance.yahoo.com - May 16 at 5:23 PM
Follow-up Phase III Data Showed Genentech’s Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live a Median of Almost Three Years Without Their Disease Worsening or DeathFollow-up Phase III Data Showed Genentech’s Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live a Median of Almost Three Years Without Their Disease Worsening or Death
finance.yahoo.com - May 16 at 5:23 PM
Phase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and PaclitaxelPhase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel
finance.yahoo.com - May 16 at 5:23 PM
[$$] No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says[$$] No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says
finance.yahoo.com - May 16 at 5:23 PM
Basal Cell Carcinoma Market Spotlight 2018-2028: Roche Leads Industry Sponsors with the Highest Number of ...Basal Cell Carcinoma Market Spotlight 2018-2028: Roche Leads Industry Sponsors with the Highest Number of ...
www.businesswire.com - May 14 at 5:10 PM
Roche Holding AG (RHHBY) Given Average Recommendation of "Hold" by BrokeragesRoche Holding AG (RHHBY) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 14 at 1:50 AM
The story of how Bill Gates's dad saved StarbucksThe story of how Bill Gates's dad saved Starbucks
finance.yahoo.com - May 13 at 6:16 PM
Keytruda Continues to Be Major Growth Driver for Merck in 2018Keytruda Continues to Be Major Growth Driver for Merck in 2018
finance.yahoo.com - May 11 at 8:52 AM
Roche (RHHBY) Lowered to Market Perform at Sanford C. BernsteinRoche (RHHBY) Lowered to Market Perform at Sanford C. Bernstein
www.americanbankingnews.com - May 10 at 6:23 PM
Setback to Roche hopes for Tecentriq as fails key cancer trialSetback to Roche hopes for Tecentriq as fails key cancer trial
www.reuters.com - May 10 at 5:39 PM
Roches Tecentriq combo wins fast FDA review in race to catch rivalsRoche's Tecentriq combo wins fast FDA review in race to catch rivals
finance.yahoo.com - May 7 at 8:33 AM
The Swiss Stock Market Climbed On Roche StrengthThe Swiss Stock Market Climbed On Roche Strength
www.nasdaq.com - April 30 at 5:04 PM
Roche Drifting Without Perception-Changing DataRoche Drifting Without Perception-Changing Data
seekingalpha.com - April 30 at 5:04 PM
How Vertex Pharmaceuticals’ Drugs Performed in 1Q18How Vertex Pharmaceuticals’ Drugs Performed in 1Q18
finance.yahoo.com - April 27 at 5:06 PM
[$$] Roche Raises Outlook After Sales Rise[$$] Roche Raises Outlook After Sales Rise
finance.yahoo.com - April 26 at 8:29 AM
Roche CEO 'Very Confident' on European Sales GrowthRoche CEO 'Very Confident' on European Sales Growth
finance.yahoo.com - April 26 at 8:29 AM
UPDATE 4-Biosimilar worries takes shine off Roches guidance hikeUPDATE 4-Biosimilar worries takes shine off Roche's guidance hike
finance.yahoo.com - April 26 at 8:29 AM
Biosimilar worries takes shine off Roches guidance hikeBiosimilar worries takes shine off Roche's guidance hike
finance.yahoo.com - April 26 at 8:29 AM
Global Biopharmaceutical Market 2018-2023 - Key Players are Roche, Amgen, Novo Nordisk, AbbVie and SanofiGlobal Biopharmaceutical Market 2018-2023 - Key Players are Roche, Amgen, Novo Nordisk, AbbVie and Sanofi
www.prnewswire.com - April 24 at 5:25 PM
Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran, Joins MyDx Executive ...Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran, Joins MyDx Executive ...
globenewswire.com - April 24 at 5:25 PM
Roche (RHHBY) Presents Encouraging Data on MS Drug OcrevusRoche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
finance.yahoo.com - April 23 at 5:03 PM
FDA declines to approve Pfizer biosimilar of Roches cancer drugFDA declines to approve Pfizer biosimilar of Roche's cancer drug
finance.yahoo.com - April 23 at 5:03 PM
Pfizer says FDA failed to approve Herceptin biosimilarPfizer says FDA failed to approve Herceptin biosimilar
finance.yahoo.com - April 23 at 8:26 AM
UBS Lowers Roche (RHHBY) to NeutralUBS Lowers Roche (RHHBY) to Neutral
www.americanbankingnews.com - April 19 at 8:00 PM
Cowen Analysts Give Roche (RHHBY) a $38.00 Price TargetCowen Analysts Give Roche (RHHBY) a $38.00 Price Target
www.americanbankingnews.com - April 19 at 12:16 PM
Roche Holding AG (RHHBY) Receives Consensus Rating of "Hold" from AnalystsRoche Holding AG (RHHBY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 19 at 1:52 AM
How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
finance.yahoo.com - April 18 at 5:33 PM
We are going to have lung cancer patients living longer and better: A new kind of cancer treatment is about to change ...'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to change ...
www.businessinsider.com - April 16 at 5:09 PM
Roche Stumbles On Combo Trial Halt, Should You Still Buy?Roche Stumbles On Combo Trial Halt, Should You Still Buy?
seekingalpha.com - April 16 at 5:09 PM
How AbbVie’s Humira Performed in 4Q17 and 2017How AbbVie’s Humira Performed in 4Q17 and 2017
finance.yahoo.com - April 16 at 5:09 PM
Roche Holding AG (RHHBY) Forecasted to Post FY2021 Earnings of $2.77 Per ShareRoche Holding AG (RHHBY) Forecasted to Post FY2021 Earnings of $2.77 Per Share
www.americanbankingnews.com - April 16 at 3:03 AM
Roches (RHHBY) "Equal Weight" Rating Reaffirmed at Morgan StanleyRoche's (RHHBY) "Equal Weight" Rating Reaffirmed at Morgan Stanley
www.americanbankingnews.com - April 15 at 8:54 PM
3 Things In Biotech, April 13: Roche Pipes Up, Cara Updates, Bellicum Marches On3 Things In Biotech, April 13: Roche Pipes Up, Cara Updates, Bellicum Marches On
seekingalpha.com - April 14 at 5:00 PM
Were about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are ...We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are ...
www.businessinsider.com - April 13 at 5:18 PM
Roche on Damage Control after Hemlibra Patient DeathsRoche on Damage Control after Hemlibra Patient Deaths
finance.yahoo.com - April 13 at 8:40 AM
Recent Developments with Roche’s Lung Cancer Drug TecentriqRecent Developments with Roche’s Lung Cancer Drug Tecentriq
finance.yahoo.com - April 12 at 5:22 PM
Roche Gets Lung Cancer Drug Alecensa Approval in Swiss MarketRoche Gets Lung Cancer Drug Alecensa Approval in Swiss Market
finance.yahoo.com - April 12 at 5:22 PM
Why NICE Didn’t Approve Roche’s Ocrevus for Multiple SclerosisWhy NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis
finance.yahoo.com - April 12 at 5:22 PM
Roche’s Ocrevus Is a Highly Effective Option for MS TreatmentRoche’s Ocrevus Is a Highly Effective Option for MS Treatment
finance.yahoo.com - April 12 at 5:22 PM
What Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial StrengthWhat Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial Strength
finance.yahoo.com - April 12 at 9:01 AM
Roche (RHHBY) Downgraded by Zacks Investment Research to "Sell"Roche (RHHBY) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 11 at 12:04 PM

SEC Filings

Roche (OTCMKTS:RHHBY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Roche (OTCMKTS RHHBY) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.